EUVIMEDEUVIMED entdecken
Klinische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Efficacy, Quality of Life, and Cost‐Effectiveness of Superselective Adrenal Arterial Embolization in Idiopathic Hyperaldosteronism: A Comparative Study

Nouman Ali Khan, Min Mao, Rui Feng, Zhong Zuo, Muhammad Arif Asghar, Li Tao, Yongpeng Zhao, Ping Tang, Zhixing Xu, Jie Chen, Xin Li, Hong Zhao und 5 weitere

The Journal of Clinical Hypertension · 2025

DOI: 10.1111/jch.70115 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Nouman Ali Khan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chin…. Hauptthemen laut MEDLINE: Adrenal Glands, Embolization, Therapeutic, Hyperaldosteronism, Quality of Life. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chongqing Science Committee for funding of the General Project, Ministry of Finance and Ministry of Health of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic hyperaldosteronism (IHA) is the most common subtype of primary aldosteronism, typically managed with mineralocorticoid receptor antagonists (MRAs). However, long‐term MRA therapy is associated with suboptimal cardiovascular outcomes and adverse effects. Superselective adrenal arterial embolization (SAAE) is a novel minimally invasive alternative, but its long‐term efficacy, particularly regarding quality of life and cost‐effectiveness, remains underexplored. In this study, 62 patients with bilateral IHA were prospectively enrolled and assigned to two groups: SAAE ( n = 42) and MRA therapy ( n = 20). Outcomes, including blood pressure, serum potassium, aldosterone‐renin ratio normalization, and quality of life (measured by SF‐36 and EQ‐5D), were assessed at 12 months. A supervised Random Forest model was developed to predict treatment success. A 5‐year cost‐utility analysis compared SAAE and MRA therapy from a healthcare system perspective. Results showed that SAAE led to greater reductions in blood pressure (mean −27.4 ± 21.3 mmHg systolic, −23.1 ± 17.4 mmHg diastolic) compared to MRA therapy (−15.6 ± 11.4 mmHg systolic, −12.4 ± 10.1 mmHg diastolic, p < 0.001). Clinical success was achieved in 63.2% of the SAAE group, with biochemical remission in 39.6%. SAAE also led to greater improvements in quality of life and demonstrated lower costs and higher quality‐adjusted life years (QALYs) compared to MRA therapy. SAAE is a safe, effective, and cost‐effective treatment for IHA, offering superior blood pressure control, hormonal normalization, and improved quality of life compared to MRAs. Trial Registration : ClinicalTrials.gov identifier: ChiCTR2200062738.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal GlandsEmbolization, TherapeuticHyperaldosteronismQuality of LifeAdultFemaleHumansMaleMiddle AgedAldosteroneBlood PressureCost-Benefit AnalysisMineralocorticoid Receptor AntagonistsProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

AI predictive modelingclinical and biochemical successcost‐effectiveness analysisidiopathic hyperaldosteronismquality of life (QoL)superselective adrenal arterial embolization (SAAE)

Substanzen

AldosteroneMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Chongqing Medical University, Chongqing, China.
  • Department of Radiology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Förderung

  • Chongqing Science Committee for funding of the General Project
  • Ministry of Finance and Ministry of Health of the People's Republic of China

Zitieren

APA

Khan, N. A., Mao, M., Feng, R., Zuo, Z., Asghar, M. A., Tao, L., Zhao, Y., Tang, P., Xu, Z., Chen, J., Li, X., Zhao, H., Shi, Q., Wang, L., He, Y., Chang, J., & Xiang, R. (2025). Efficacy, Quality of Life, and Cost‐Effectiveness of Superselective Adrenal Arterial Embolization in Idiopathic Hyperaldosteronism: A Comparative Study. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.70115

Vancouver

Khan NA, Mao M, Feng R, Zuo Z, Asghar MA, Tao L, et al. Efficacy, Quality of Life, and Cost‐Effectiveness of Superselective Adrenal Arterial Embolization in Idiopathic Hyperaldosteronism: A Comparative Study. The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.70115

BibTeX
@article{Khan2025,
  author = {Khan, Nouman Ali and Mao, Min and Feng, Rui and Zuo, Zhong and Asghar, Muhammad Arif and Tao, Li and Zhao, Yongpeng and Tang, Ping and Xu, Zhixing and Chen, Jie and Li, Xin and Zhao, Hong and Shi, Qiuyue and Wang, Ling and He, Yutian and Chang, Jing and Xiang, Rui},
  title = {Efficacy, Quality of Life, and Cost‐Effectiveness of Superselective Adrenal Arterial Embolization in Idiopathic Hyperaldosteronism: A Comparative Study},
  journal = {The Journal of Clinical Hypertension},
  year = {2025},
  doi = {10.1111/jch.70115}
}
Kostenlos starten →